Abstract
Background
Circulating tumour cells (CTCs) represent a morphologically distinct subset of cancer cells, which aid the metastatic spread. The ExPeCT trial aimed to examine the effectiveness of a structured exercise programme in modulating levels of CTCs and platelet cloaking in patients with metastatic prostate cancer.
Methods
Participants (n = 61) were randomised into either standard care (control) or exercise arms. Whole blood was collected for all participants at baseline (T0), three months (T3) and six months (T6), and analysed for the presence of CTCs, CTC clusters and platelet cloaking. CTC data was correlated with clinico-pathological information.
Results
Changes in CTC number were observed within group over time, however no significant difference in CTC number was observed between groups over time. Platelet cloaking was identified in 29.5% of participants. A positive correlation between CTC number and white cell count (WCC) was observed (p = 0.0001), in addition to a positive relationship between CTC clusters and PSA levels (p = 0.0393).
Conclusion
The presence of platelet cloaking has been observed in this patient population for the first time, in addition to a significant correlation between CTC number and WCC.
Trial registration
ClincalTrials.gov identifier NCT02453139.
Funder
World Cancer Research Fund International
Publisher
Public Library of Science (PLoS)
Reference38 articles.
1. NCRI. Prostate Cancer Factsheet 2018 [https://www.ncri.ie/sites/ncri/files/factsheets/Factsheet%20prostate.pdf].
2. ACS. Survival rates for prostate cancer 2018 [https://www.cancer.org/cancer/prostate-cancer/detection-diagnosis-staging/survival-rates.html].
3. Circulating tumor cells: a window into cancer biology and metastasis;S Maheswaran;Current opinion in genetics & development,2010
4. A microfluidic device for label-free, physical capture of circulating tumor cell clusters;AF Sarioglu;Nature methods,2015
5. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer;A Goldkorn;Journal of clinical oncology: official journal of the American Society of Clinical Oncology,2014
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献